New study checks how well an antibiotic reaches the brain

NCT ID NCT06119061

Recruiting now Knowledge-focused Sponsor: Aaron Cook Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how much of the antibiotic telavancin gets into the brain fluid of 20 critically ill patients who have a drain in their head (external ventricular drain). These patients often need strong antibiotics, but it's not clear if telavancin reaches the brain well enough. Researchers will measure drug levels in blood and brain fluid after three doses to better understand how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Telavancin (Vibativ)
What this could lead to: If successful, this study could help doctors know the right dose of telavancin to treat brain infections in critically ill patients.
What could go wrong: This is a very small, early-phase study (20 people) that only measures drug levels, not whether the drug actually works or improves outcomes. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUBARACHNOID HEMORRHAGE, ANEURYSMAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SUBARACHNOID HEMORRHAGE, ANEURYSMAL

Contacts and locations

Locations

University of Kentucky
RECRUITING

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.